Compare Gilead Sciences, Inc. (GILD) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Wells Fargo & Co — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Wells Fargo & Co trades at $82 (market cap $242.71B). The key difference: Wells Fargo & Co is the larger of the two by market cap, and Wells Fargo & Co pays the higher dividend (2.49%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Wells Fargo & Co for 87 Days on average.
| GILD | WFC | |
|---|---|---|
Market Cap | $182.09B | $242.71B |
Volume | 4,960,247 | 13,542,533 |
Sector | Health | Financials |
52-Week High | $155.80 | $96.40 |
52-Week Low | $116.74 | $73.42 |
Typical Hold Time | 111 Days | 87 Days |
Enterprise Value | $205.15B | $498.47B |
Dividend Yield | 2.23% | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Wells Fargo (WFC) trades at $82.06, up 0.67% today, with a bearish technical signal despite recent earnings beat. The stock shows strong fundamentals with 25.97% net income margin and 13.13% ROE, trading at attractive valuations (P/E 11.67, P/B 1.47). Recent credit rating upgrade to 'A-' by S&P and stable Fed stress test changes provide positive catalysts, though negative operating cash flow of -$19B in 2025 raises concerns.
WFC presents a compelling value opportunity with analyst consensus target of $99.13 (21% upside), supported by improving profitability and stable regulatory environment. Key risks include volatile cash flows, rising interest rate pressures, and execution challenges in maintaining recent momentum. The balanced analyst sentiment (47% Buy, 47% Hold) suggests cautious optimism for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
